Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc.
Company type	Subsidiary
Traded as	Nasdaq: ALXN
Industry	Pharmaceutical industry
Founded	1992
Founder	Leonard Bell
Headquarters	Boston, Massachusetts, U.S.
Key people	Leonard Bell (Chairman); Ludwig N. Hantson (CEO)
Products	Eculizumab (Soliris); Ravulizumab (Ultomiris); Asfotase alfa (Strensiq); Sebelipase alfa (Kanuma); Andexanet alfa (Andexxa)
Revenue	US$6.069 billion (2020)
Net income	US$603 million (2020)
Total assets	US$18.103 billion (2020)
Total equity	US$11.651 billion (2020)
Number of employees	2,525 (2020)
Parent	AstraZeneca
Website	www.alexion.com
	Footnotes / references;

Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.

Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); asfotase alfa (Strensiq), used to treat hypophosphatasia; sebelipase alfa (Kanuma), used to treat lysosomal acid lipase deficiency, and andexanet alfa (Andexxa), used to stop life threatening or uncontrollable bleeding in people who are taking rivaroxaban or apixaban.^[1]

With costs that can reach as much as $2 million per year, the drugs manufactured by Alexion are some of the most expensive drugs worldwide.^[2]